IMNN imunon.com: Business Value
Imunon, Inc. (IMNN) specializes in creating breakthrough therapies for ovarian cancer. This price chart reflects the valuation dynamics of a business centered on the development of Placcine vaccines, with an Enterprise Value of 5.91. Imunon, Inc. (IMNN) is developing its technologies independently, with plans to license its molecules to industry behemoths in the future. Simultaneously, the company is implementing ESG principles through energy efficiency and strict bio-waste control.
Imunon (IMNN) - metric breakdowns and financial figures
The historical enterprise value chart reflects the market status of Imunon, Inc. (IMNN) as a biotech startup. This metric aggregates market capitalization and net debt to determine the actual buyout price of the business. The metric is sensitive to cash reserves, which are critical for funding expensive R&D projects. High production costs for gene vectors make the company dependent on liquidity. The indicator's trend allows for an assessment of financial stability in the absence of operating leverage.